SEC Form 4 · accession 0000919574-19-001040
Insight Molecular Diagnostics Inc. · IMDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
BROADWOOD PARTNERS, L.P.
10% Owner
BROADWOOD CAPITAL INC
10% Owner
Neal C Bradsher
10% Owner
Period of report
Feb 8, 2019
Accepted (ET)
Feb 12, 2019 · 5:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001642380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, no par valueF1 | Feb 8, 2019 | P | 533,333 | $3.75 | A | 8,098,267 | D | |
| Common Stock, no par valueF2 | Feb 8, 2019 | P | 0 | $3.75 | A | 8,098,267 | I | See Footnote |
| Common Stock, no par valueF3 | holding | — | — | — | 3,145 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These securities are directly owned by Broadwood Partners, L.P.
- F2The reported securities are directly owned by Broadwood Partners, L.P. and may be deemed to be beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners, L.P. and Neal C. Bradsher as President of Broadwood Capital, Inc. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F3The securities are directly owned by Neal C. Bradsher.